

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07F 9/6568, 9/50, 17/02 // C07M 7:00	A1	(11) International Publication Number: WO 99/24444 (43) International Publication Date: 20 May 1999 (20.05.99)
(21) International Application Number: PCT/GB98/03321 (22) International Filing Date: 5 November 1998 (05.11.98) (30) Priority Data: 9723583.2 7 November 1997 (07.11.97) GB 60/068,675 24 December 1997 (24.12.97) US (71) Applicant (for all designated States except US): CHIROTECH TECHNOLOGY LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): BERENS, Ulrich [DE/GB]; Chirotech Technology Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PROCESS FOR PREPARING CYCLIC PHOSPHINES (57) Abstract The preparation of a cyclic phosphine from the corresponding primary phosphine and a bifunctional alkylating agent, wherein alkylation, and displacement of each functional group, occurs in the presence of a strong base, is modified by adding the strong base, in an amount sufficient for cyclisation, to a preformed mixture or reaction product of the primary phosphine and the alkylating agent.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



PROCESS FOR PREPARING CYCLIC PHOSPHINES

Field of the Invention

This invention relates to processes suitable for the large-scale preparation of enantiomerically-enriched cyclic phosphines, especially those useful as ligands in asymmetric hydrogenation catalysts.

Background of the Invention

Chiral cyclic phosphines are useful ligands for asymmetric catalysis. In particular, chiral ligands of the DuPHOS and BPE series, respectively represented by formulae (1) and (2)




wherein R¹ and R² are typically C₁₋₆ linear or branched alkyl, and enantiomeric forms thereof, can be used to prepare rhodium and ruthenium complexes, which are effective and versatile catalysts for asymmetric hydrogenation of a diverse range of substrate types. For a review, see Burk *et al*, Pure Appl. Chem. (1996) 68:37-44.

Such catalysts are eminently suitable for industrial applications, especially for the provision of chiral pharmaceutical intermediates in high enantiomeric purity. For this purpose, and in other industrial applications such as flavour and fragrance fine chemicals, the development of manufacturing processes requires in turn large amounts of a ligand (1) or (2), e.g. in kilogramme quantity or greater. Thus, there is a requirement for efficient and scaleable methods for synthesis of such ligands.

As described in US-A-5532395 and WO 93/01199, an established procedure for the preparation of DuPHOS and BPE ligands entails the reaction of a bis(primary)phosphine with a 1,4-alkanediol cyclic sulphate mediated by a strong base capable of deprotonating a P-H bond, typically n-butyllithium. 2 Equivalents of the cyclic

sulphate, optionally in a small excess, and at least 4 equivalents of base are required. A representative process of this type, for the preparation of (*S,S*)-methyl DuPHOS, is shown in the following scheme:

5



The literature procedure stipulates that reactants should be added to the reaction vessel in the following order:

- (a) 2 equivalents of n-butyllithium are added to a solution of 1,2-bis(phosphino)benzene in THF at 20-30°C, ostensibly to generate dilithium 1,2-bis(phosphido)benzene;
- (b) after 1-1.5 h, a solution of (*R,R*)-1,4-hexanediol cyclic sulphate (2 equivalents) in THF is added to the resultant mixture;
- (c) after a further 1 h, a second aliquot of n-butyllithium (2.2-2.3 equivalents) is added;
- (d) at the end of the reaction, work-up comprises addition of methanol and successive cycles of filtration, solvent washing and solvent evaporation, with progressive reduction in solvent polarity (diethyl ether, then pentane). An aqueous work-up is avoided.

The protocol described above is well suited to laboratory-scale synthesis of a ligand of formula (1) or (2), typically to prepare 1-10 g quantities. At this scale, operating parameters such as temperature, reaction duration, request stoichiometry, and exclusion of air and moisture are easily controlled. However, on a larger scale, it has been found that it is more difficult to achieve the same yield of the ligand, and that side-reactions can

hinder ligand purification. This may be a consequence of one or more factors, such as inadequate exclusion of air and moisture in a manufacturing plant vessel, and, in order to maintain temperature control, prolonged duration of reagent addition and overall reaction time. Without wishing to be bound by theory, anionic species generated in step (a) have
5 a longer residence time, and may be consumed by reaction with the solvent (THF). Thus yields in steps (b) and (c) are reduced.

For example, US-A-5532395 describes the preparation of (*S,S*)-methyl DuPHOS from 0.8 g of 1,2-bis(phosphino)benzene, in which a yield of 78% is achieved. In contrast, when scaling up this procedure by a factor of 75, using 60 g of 1,2-bis(phosphino)benzene,
10 the yield of methyl DuPHOS can fall to below 30%. Overall, such lowering of yield has an adverse effect on the economics of the process.

Wilson and Pasternak, Synlett 4:199-200 (April 1990), discloses the preparation of chiral phosphines for use in an asymmetric Staudinger reaction.

US-A-5399771 discloses the preparation of BINAP using diphenylphosphine, an
15 amine base and a nickel catalyst.

GB-A-2262284 discloses the preparation of tertiary phosphines.

Summary of the Invention




This invention is based on the discovery that an efficient, high-yielding preparation of a cyclic phosphine is facilitated by a new mode of reagent addition. More specifically,
20 a process for the preparation of a cyclic phosphine from the corresponding primary phosphine and a bifunctional alkylating agent, wherein alkylation, and displacement of each functional group, occurs in the presence of a strong base, comprises adding the strong base, in an amount sufficient for cyclisation, to a preformed mixture or reaction product of the primary phosphine and alkylating agent.

25 It is surprising that high yields are achieved in this process, given the potential for side-reactions, which an individual of ordinary skill in the art might predict. In particular, the bifunctional alkylating agent is susceptible to β -elimination by reaction with a strong base. However, in practice, β -elimination is not observed as a major reaction pathway. Also noteworthy is the fact that this process allows the preparation of phosphines bearing
30 very hindered functional groups such as *tert*-butyl through substitution at neopentyl-like centres of the alkylating agent.

In addition to improvements in yield and product purity, simplicity of process operation is another benefit when compared to the original protocol, since all of the base required to mediate the reaction is added in a single operation, after the reaction vessel has been charged with all other reactants. Moreover, it is found that, in general, cyclic phosphines withstand aqueous work-up, which is advantageous in terms of material transfer/handling, allowing convenient separation of ionic species (salts, *etc*) from the product.

Description of the Invention

The process of this invention preferably comprises the addition of at least 2m equivalents of a strong base to a mixture or reaction product of the primary phosphine and at least m equivalents of the bifunctional alkylating agent. The cyclic phosphine, the primary phosphine and the bifunctional alkylating agent that are used in this invention are preferably respectively of formula (3), (4) and (5)




In formulae (3)-(5), R¹ and R² are independently H, alkyl, cycloalkyl, aryl, aralkyl or alkaryl, provided that both are not H, R³ is aryl, alkyl, cycloalkyl, aralkyl, alkaryl, or an organometallic residue such as ferrocenyl; m is 1 or 2; n is in the range 1-4; and X and X¹ are the same or different nucleofugal leaving groups, optionally linked to form a ring. The cyclic phosphine ring in (3) may optionally form part of a fused polycyclic ring system.

Any base capable of effecting complete deprotonation of a P-H bond is suitable for use in the novel process. Commercially available organolithium bases are ideal for this purpose and alkylolithiums are preferred, especially n-butyllithium and sec-butyllithium. A variety of solvents may be used, particularly ethereal solvents such as tetrahydrofuran (THF), diglyme, diethyl ether or t-butyl methyl ether. THF is the preferred solvent, and

hydrocarbon solvents, e.g. hexanes, such as might be used for dissolution of an organolithium base, are compatible as cosolvents.

A preferred embodiment of the present invention is a process for preparation of enantiomerically-enriched ligands of formula (3), from enantiomerically-enriched alkylating agents of formula (5). The degree of enrichment is typically at least 70% ee, preferably at least 80% ee, more preferably at least 90% ee, and most preferably at least 95% ee.

Further, it is preferred that R^1 and R^2 are orientated *trans* to one another. Usually, although not necessarily, R^1 and R^2 are the same. This encompasses ligands of the DuPHOS (1) and BPE (2) series and monophosphospholane variants thereof. Further, it includes the use of phosphetane ligands, as disclosed in WO 98/02445, of formula (6)




15

For monophosphetanes (6) wherein $Y = Ph$, the process of the present invention is especially advantageous, since transfer of a solution of lithiated phenylphosphine between reaction vessels is avoided, thereby reducing the exposure risk to this noxious and foul-smelling substance.

20

In another embodiment of the present invention, the preparation of novel ferrocenyl bisphosphetanes of formula (7)



25

30

and opposite enantiomers thereof, wherein R^1 and R^2 are linear or branched alkyl, demonstrates functional group compatibility. In the case of compounds of formula (7)

wherein $R^1 = R^2 = t\text{-Bu}$, controlled nucleophilic substitution at neopentyl-like centres may be achieved.

For preparation of ligands of formulae (1), (2), (6) and (7), and related compounds, preferred bifunctional alkylating agents are those prepared from the corresponding single enantiomer 1,3- and 1,4-diols. Cyclic sulphate derivatives are preferred, although bis(aryl)sulphonates or bis(alkyl)sulphonates, such as ditosylates, can be used with equal facility. 1,4-Diol precursors of phospholane ligands (1) and (2) can be prepared either by electrochemical Kolbe coupling [see Burk *et al*, *Organometallics* (1990) 9:2653] or more conveniently via biocatalytic resolution of racemic diols [Berens, Proceedings of Chiral Europe 1996 (Spring Innovations Ltd.), p. 13]. 1,3-Diol precursors of phosphetanes (6) are easily accessible by asymmetric hydrogenation of the corresponding 1,3-diketones (for lead references, see WO 98/02445).

The following Examples illustrate the invention.

Example 1 1,2-bis((2*R*,5*R*)-2,5-Dimethylphospholano)benzene (*R,R*)-MeDuPHOS

A solution of *n*-BuLi in hexanes (2.958 mol; 1.183 L of 2.5 N solution), diluted with diethyl ether (2.5 L), was added over 4 hours to a stirred mixture of 1,2-bis(phosphino)benzene (100 g, 0.7042 mol) and the cyclic sulfate (4*R*,7*R*)-4,7-dimethyl-2,2-dioxo-1,3,2-dioxathiepane (266.5 g, 1.479 mol, 5% excess) in THF (8 L), under a nitrogen atmosphere, whilst maintaining an internal temperature of 10-15°C. After the BuLi-solution had been added completely, the mixture was stirred for another 10 minutes, and then quenched by the addition of water (ca. 20 mL). The solvent was evaporated on a rotavapor, and to the residue was added water (ca. 1 L) to dissolve the lithium sulfate. The pH was adjusted to 3 by the addition of diluted (2 N) sulfuric acid. The ligand was extracted from this mixture with tert-butyl methyl ether (1 x 1 L, 3 x 500 ml). After drying and removal of the solvent, methanol (ca. 500 ml) was added carefully to the crude ligand to induce crystallisation. After standing overnight in the refrigerator, the crystals were filtered off and dried in vacuum. Evaporating the solvent from the filtrate and recrystallisation of the residue from little MeOH yielded another crop of Me-DuPHOS. White crystals, mp. = 80-81°C; combined yield 151g (70.0% based on 1,2-bis-(diphosphino)benzene).

Example 2 (2*S*,5*S*)-2,5-Dimethyl-1-(naphth-1-yl)phospholane

A solution of n-BuLi in hexanes (21 mmol; 8.4 ml of 2.5 N solution), diluted with diethyl ether (20 ml), was added over 30 minutes to a stirred mixture of 1-naphthylphosphine (1.6 g, 10 mmol) and the cyclic sulfate (4*R*,7*R*)-4,7-dimethyl-2,2-dioxo-1,3,2-dioxathiepane (1.89 g, 10.5 mmol, 5% excess) in THF (100 ml), under a nitrogen atmosphere. After the complete addition of BuLi, the deep orange mixture was stirred for another 10 minutes, and then quenched by the addition of MeOH (2 ml). Then the solvent was removed on the rotavapor, and to the residue was added water. The product was extracted with pentane (3 x 50 ml) and, after drying the combined organic layers and removal of the solvent, the essentially pure phosphine was obtained as an oil. Yield 1.73 g (71.1% based on naphthylphosphine). ³¹P-NMR (CDCl₃, 400 MHz): δ = -6.00 ppm.

Example 3 *cis*- and *trans*- *meso*-2,5-Dimethyl-1-phenylphospholane

A solution of n-BuLi in hexanes (21 mmol; 8.4 ml of 2.5 N solution), diluted with diethyl ether (20 ml), was added over 30 minutes to a stirred mixture of phenylphosphine (1.1 g, 10 mmol) and *meso*-2,5-di-O-tosyl-hexane (4.48 g, 10.5 mmol, 5% excess) in THF (150 ml), under a nitrogen atmosphere. After the complete addition of the BuLi, the solvent, was removed from the reaction mixture on the rotavapor. To the residue was added water, and the product was extracted with pentane in three portions (50 ml each). After drying the combined organic layers and removal of the solvent, the product was obtained as an oil. Yield 1.72 g (89.5% based on phenylphosphine) of a 88:12 mixture of *trans*- and *cis-meso*-2,5-dimethyl-1-phenyl-phospholane.

Example 4 (2*R*,4*R*)-2,4-Diethyl-1-phenylphosphetane

A solution of n-BuLi in hexanes (88 ml of 2.5 N solution), diluted with diethyl ether (400 ml), was added over 3 hours to a stirred mixture of phenylphosphine (10.0 g, 90.1 mmol) and the cyclic sulfate (4*S*,7*S*)-4,7-diethyl-2,2-dioxo-1,3,2-dioxathian (19.6 g, 0.1 mol, 10% excess) in THF (1 L), under a nitrogen atmosphere. The mixture was maintained at a temperature of -30°C during the first half of the addition period, with cooling to -75°C for the second half. The mixture was then left to warm overnight. After removal of the solvent, pentane (250 ml) and water (100 ml) were added to the residue. The organic layer was dried, and the solvent was removed to leave the phosphetane as a pale yellow oil which was pure with the exception of a small amount of unreacted

phenylphosphine as impurity. After distillation (bp. = 81°C at 0.05 mm), 9.94 g of (2*R*,4*R*)-2,4-diethyl-1-phenylphosphetane (53% yield based on phenylphosphine) was obtained.

Example 5 1,2-Bis((2*S*,5*S*)-2,5-diethylphospholano)ethane (*S,S*)-Et-BPE

5 1,2-Bis(phosphino)ethane (12.0 g, 0.1276 mol) was added to a solution of the cyclic sulfate (4*R*,7*R*)-4,7-diethyl-2,2-dioxo-1,3,2-dioxathiepane (55.9 g, 0.2683 mol, 5% excess) in 1 L of THF, under nitrogen. A solution of 2.5 N n-BuLi (211.3 ml, 0.528 mol) in ether (300 ml), was added under rapid stirring within 120 minutes, while the internal temperature was maintained at 10°C by cooling with an ice bath. After the complete
10 addition of the BuLi there was no colour, thus more BuLi (ca. 10 ml) was added, until the colour was yellow. The mixture was then quenched by the addition of MeOH (5 ml), and the solvent was removed on the rotavapor. To the residue was added water (150 ml), and the product was extracted with pentane (3 x 80 ml). After drying of the combined organic layers (Na₂SO₄) and removal of the solvent, the essentially pure phosphine was obtained
15 as an oil. Distillation over a 30 cm Vigreux column gave a fraction boiling from 140 to 143°C at 0.02 mm, which contained 34.02 g of pure ligand (84.8% based on 1,2-bis(phosphino)ethane).

Example 6 1,1'-bis((2*S*,4*S*)-2,4-diisopropylphosphetan-1-yl)ferrocene

A solution of the cyclic sulfate (4*R*,6*R*)-4,6-diisopropyl-2,2-dioxo-1,3,2-dioxathiolane (3.7 g, 16.8 mmol, 5% excess) in 200 mL of THF in a 500 mL flask was
20 sparged with nitrogen for 45 minutes. A dropping funnel which was attached to the middle neck of the flask was charged with a solution of 1.3 N sec-BuLi (31.0 ml, 40.3 mmol) in pentanes (100 mL). Under exclusion of air, 1,1'-bis(phosphino)ferrocene (2.0 g, 8 mmol) was added *via* syringe to the solution of the cyclic sulfate (no stirring), and
25 then the solution of sec-BuLi was added at 0°C under rapid stirring within one hour. When the addition of the sec-BuLi was complete, the mixture was stirred for another 2 minutes and then the excess base was quenched by the addition of 2 mL of MeOH. The solvent was then removed on the rotavapor, and the residue was dissolved in water/saturated NH₄Cl (100/50mL). This mixture was extracted twice with petrol ether (bp. 40-60°C, 100
30 and 50 mL). The combined organic layer was dried (Na₂SO₄), and removal of the solvent gave 3.99 g of a crystalline material. This was redissolved in ca. 5 mL of petrol ether, and


after the addition of ca. 20 mL of methanol, the product crystallised. Fine yellow needles, 2.85 g, 71.5% yield, mp = 115-116°C by DSC.

Example 7 1,1'-bis((2*S*,4*S*)-2,4-di-*tert*-butylphosphetan-1-yl)ferrocene

A solution of the cyclic sulfate (4*R*,6*R*)-4,6-di-*t*-butyl-2,2-dioxo-1,3,2-dioxathiolane (4.2 g, 16.8 mmol, 5% excess) in 300 mL of THF in a 500 mL flask was sparged with nitrogen for 45 minutes. A dropping funnel which was attached to the middle neck of the flask was charged with a solution of 1.3 N sec-BuLi (27.1 ml, 35.2 mmol) in pentanes (50 mL). Under exclusion of air, 1,1'-bis(phosphino)ferrocene (2.0 g, 8 mmol) was added *via* syringe to the solution of the cyclic sulfate (no stirring), and then the solution of sec-BuLi was added at 0°C under rapid stirring within one hour. After the complete addition of the sec-BuLi the mixture was stirred for another 10 minutes and then the excess base was quenched by the addition of methanol. The solvent was then removed on the rotavapor, and the residue was distributed between water/pentane (100 and 2 x 50mL of pentane). The combined organic layer was dried (Na₂SO₄), and removal of the solvent gave 3.4 g of a bright yellow-orange solid. The material was recrystallised from methanol (ca. 50 mL) and gave, after two recrystallisations, 1.12g (25%) of the product.

CLAIMS

1. A process for the preparation of a cyclic phosphine from the corresponding primary phosphine and a bifunctional alkylating agent, wherein alkylation, and displacement of each functional group, occurs in the presence of a strong base, which
 5 comprises adding the strong base, in an amount sufficient for cyclisation, to a preformed mixture or reaction product of the primary phosphine and the alkylating agent.
2. A process according to claim 1, which comprises the addition of at least 2m equivalents of the strong base to a mixture or reaction product of the primary phosphine and at least m equivalents of the bifunctional alkylating agent.
- 10 3. A process according to claim 1 or claim 2, wherein the cyclic phosphine is of formula (3), the primary phosphine is of formula (4) and the alkylating agent is of formula (5)




wherein m and n are positive integers, the various groups R are each any non-interfering radical, and X and X¹ are each nucleofugal leaving groups, optionally linked to form a ring.


4. A process according to claim 3, for the preparation of an enantiomerically-enriched cyclic phosphine (3) from an enantiomerically-enriched alkylating agent (5).
- 25 5. A process according to claim 3 or claim 4, wherein the orientation of R¹ and R² in the phosphine (3) is *trans*.
6. A process according to any of claims 3 to 5, wherein R¹ and R² are independently H, alkyl, cycloalkyl, aryl, aralkyl or alkaryl, provided that both are not H, R³ is aryl, alkyl, cycloalkyl, aralkyl, alkaryl or an organometallic residue; m is 1 or 2; n is an integer of 1-4;
 30 and wherein the cyclic phosphine ring in (3) optionally forms part of a fused polycyclic ring system.

7. A process according to claim 6, wherein $R^1=R^2$ and n is 1 or 2.
8. A process according to claim 7, wherein n is 2.
9. A process according to claim 8, wherein m is 2.
10. A process according to claim 9, wherein the primary phosphine (4) is 1,2-bis(phosphino)benzene or 1,2-bis(phosphino)ethane, for the preparation of a cyclic diphosphine of formula (1) or (2)

10



15



or the opposite enantiomer thereof, wherein $R^1=R^2$ =linear or branched C_{1-6} alkyl.

11. A process according to claim 8, wherein m is 1 and R^3 is aryl.
12. A process according to claim 7, wherein n is 1.
13. A process according to claim 12, wherein m is 2.
14. A process according to claim 13, wherein R^3 is ferrocenyl.
15. A process according to claim 12, wherein m is 1 and R^3 is aryl.
16. A process according to any preceding claim, wherein the bifunctional alkylating agent is obtainable from the corresponding alkanediol, i.e. $X=X^1=OH$ if the alkylating agent is of formula (5).
17. A process according to any preceding claim, wherein the alkylating agent is a cyclic sulphate, i.e. X and X^1 are linked if the alkylating agent is of formula (5).
18. A process according to any preceding claim, wherein the base is an alkyl or aryl lithium.
19. A process according to claim 18, wherein the base is n -butyllithium or sec -butyllithium.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/03321

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07F9/6568 C07F9/50 C07F17/02 //C07M7:00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 01199 A (E.I. DU PONT DE NEMOURS) 21 January 1993 cited in the application see the whole document ---	1-19
Y	WILSON S R ET AL: "PREPARATION OF A NEW CLASS OF C2-SYMMETRIC CHIRAL PHOSPHINES: THE FIRST ASYMMETRIC STAUDINGER REACTION" SYNLETT, no. 4, 1 April 1990, page 199/200 XP000114769 cited in the application see the whole document ---	1-19
Y	US 5 399 771 A (DONGWEI CAI) 21 March 1995 cited in the application see the whole document ---	1-19
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

1 February 1999

Date of mailing of the international search report

12/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

Inte Application No

PCT/GB 98/03321

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GB 2 262 284 A (HOECHST AG) 16 June 1993 cited in the application see the whole document ---	1-19
P, Y	WO 98 02445 A (CHIROSCIENCE LTD.) 22 January 1998 cited in the application see the whole document -----	1-19

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 98/03321

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9301199 A	21-01-1993	US 5171892 A	15-12-1992
		AT 153667 T	15-06-1997
		DE 69220061 D	03-07-1997
		DE 69220061 T	11-09-1997
		EP 0592552 A	20-04-1994
		ES 2103953 T	01-10-1997
		JP 6508848 T	06-10-1994
		US 5386061 A	31-01-1995
		US 5565593 A	15-10-1996
		US 5559267 A	24-09-1996
		US 5596114 A	21-01-1997
		US 5532395 A	02-07-1996
		US 5329015 A	12-07-1994
US 5399771 A	21-03-1995	AU 2654895 A	21-12-1995
		JP 10501234 T	03-02-1998
		WO 9532934 A	07-12-1995
GB 2262284 A	16-06-1993	DE 4141299 A	17-06-1993
		CA 2084738 A	15-06-1993
		JP 5255362 A	05-10-1993
		US 5268479 A	07-12-1993
WO 9802445 A	22-01-1998	AU 3626997 A	09-02-1998